• Heterogeneous cytogenetic groups can be classified into good-, intermediate-, and poor-risk on the basis of prognosis.
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Introduction
Acute megakaryoblastic leukemia (AMKL) occurs predominantly in children and comprises up to 10% of pediatric acute myeloid leukemia (AML) cases. [1] [2] [3] [4] AMKL blasts show cytoplasmic blebs and are immunophenotypically positive for CD41, CD42b, and CD61. However, the diagnosis of AMKL may be difficult because of myelofibrosis and manifestation as extramedullary disease.
AMKL is characterized by various chromosomal abnormalities that are frequently associated with complex karyotypes and hyperdiploidy. 5 A study on 30 children and 23 adults with AMKL described 9 cytogenetic subgroups: normal karyotypes (I); Down syndrome (DS) (II); numerical abnormalities only (III); t(1;22)(p13;q13)/OTT-MAL (IV); t(9;22)(q34;q11.2) (V); 3q21q26 (VI); -5/5q-, -7/7q-, or both (VII); i(12)(p10) (VIII); and other structural changes (IX). 4 Groups I-IV were mostly seen in children and groups V-VIII mainly in adults. AMKL is the most frequent form of AML in young children (<4 years) with DS, which is currently recognized as a distinct form of leukemia (myeloid leukemia associated with Down syndrome) in the 2008 World Health Organization (WHO) classification and has an excellent prognosis. 6, 7 It is often preceded by the transient myeloproliferative disorder (TMD), and GATA1 mutations are detected in nearly all patients. In children with non-DS AMKL, numerical chromosomal abnormalities, especially +8, +19, and +21, are commonly seen. [1] [2] [3] The t(1;22)(p13;q13)
is restricted to AMKL and observed in non-DS infants. 4 Among patients with AMKL treated at St. Jude Children's Research Hospital (St.
Jude), non-DS patients (n=28) had a significantly worse 2-year event-free survival (EFS) (14%) than DS patients (n=6, 83%). 1 Similarly, 53 children with AMKL treated on
For personal use only. on January 15, 2018 . by guest www.bloodjournal.org From the CCG2891 protocol had a 5-year EFS of 22.5%. 8 However, the Japanese groups reported a 10-year EFS of 57% for children with non-DS AMKL (n=21), 2 and the BerlinFrankfurt-Münster (BFM) AML04 study reported improvement in 5-year EFS (n=60; 54%). 9 The BFM group attributed this improvement to the higher cumulative dosage of cytarabine (48-fold) and anthracyclines (1.2-to 1.6-fold) in the BFM93/98 protocols than the BFM87 study. 3 However, the benefit of allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains contradictory. Patients with non-DS AMKL had significantly better 2-year EFS after allo-HSCT (26%) than after chemotherapy alone (0%) in a St. Jude study, 1 
and the European Group for Blood and Bone Marrow
Transplantation study reported a 3-year leukemia-free survival of 66% after allo-HSCT (n=19) in children with AMKL, although this study included DS patients. 10 However, the BFM and Japanese studies did not document a benefit of allo-HSCT. 2, 3, 9 The prognostic impact of cytogenetically defined subgroups in AMKL has not yet been clearly defined, except in a St. Jude AML02 multicenter study in which EFS and overall survival (OS) for patients with AMKL and t(1;22) (n=5) were better than for those with AMKL without t(1;22) (n=21). 11, 12 All previous studies on AMKL were conducted on small numbers of patients.
Herein, we conducted an international, large-scale retrospective study of children with 
Patients and methods

Patients
De-identified data on pediatric patients with AMKL were collected from 19 members of the international BFM (I-BFM) Study Group (supplemental Table 1 ). Inclusion criteria were age 0-18 years; de novo AMKL; and diagnosis between January 1, 1989 and December 31, 2009. AMKL was diagnosed according to the following criteria: expression of the megakaryocytic antigen profile in leukemia blasts by flow-cytometry (CD41, CD42b, or CD61) or immunohistochemistry (CD42b, CD61, CD31, or Factor VIII) or detection of platelet peroxidase activity by electron microscopy. Exclusion criteria were AMKL as secondary malignancy; previous chemotherapy or radiotherapy for malignant disease; and DS-associated AMKL including mosaicism. Records were studied for clinical features at initial diagnosis, treatment including HSCT, and events during follow-up. Treatment protocols were administered in accordance with local laws and guidelines and approved by institutional review boards of participating centers.
Informed consent was obtained from patients' parents or legal guardians in accordance with the Declaration of Helsinki.
Cytogenetic analysis
Submitted karyotypes were centrally reviewed by a cytogeneticist (S.C.R.), using standard nomenclature according to the International System for Human Cytogenetic Nomenclature 2009. 13 
Statistical analyses
Complete remission (CR) was defined as bone marrow with <5% blasts and evidence of regeneration of normal hematopoietic cells. EFS was defined as time from diagnosis to first event, including failure to achieve remission, relapse, secondary malignancy, or death from any cause. Patients who did not achieve CR were considered to have an event at time zero. OS was calculated from diagnosis to death from any cause. Early death was defined when the event occurred within 30 days from diagnosis. The KaplanMeier method was used to estimate 5-year probabilities of EFS and OS, 14 and survival distributions between groups were compared by the log-rank test.
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All P-values were two tailed. Multivariable Cox regression analyses using variables with P≤0.1 in univariate analysis were performed on EFS and OS. Backward selection was used to assess variables with an independent significant effect at a significance level of 0.05 in the final model.
Results
Patient characteristics
The study included 490 patients with AMKL ( /L); males and females were equally represented.
Extramedullary disease was recorded in 69 (14.1%) patients: 23 central nervous system (CNS), 13 lymph nodes, 11 skin, 10 bone, 7 orbit/sinus, 4 gonad, and 9 not specified.
Multiple treatment protocols were used by participating groups (supplemental Table 2 ). Table 3 ). There were no associations between extramedullary or CNS disease and EFS or OS. Two patients developed second malignancies: B lymphoblastic leukemia (n=1) and solid tumor (n=1, details unknown).
Cytogenetic analysis
Of the 490 patients, cytogenetic data were available for 372 (75.9%) ( Table 1) . The remaining 118 patients were not evaluated for different reasons (24 with normal karyotype but <20 analyzed metaphases, 26 for whom cytogenetic description of the abnormality was incomplete, and 68 for whom information was not available).
Compared with patients for whom cytogenetic data were not available, patients for whom data were available had higher initial WBC counts and were more frequently diagnosed in 2000-2009 (supplemental Table 4 ). Among 372 evaluable patients, modal number analysis showed hypodiploidy (n=18, 4.8%), normal karyotype (n=49, 13.2%), pseudodiploidy (n=119, 32.0%), 47-50 chromosomes (n=142, 38.2%), and >50 chromosomes (n=44, 11.8%) ( Figure 2A , (Table 2) .
Specific recurrent chromosomal abnormalities
For whole numerical abnormalities, 195 of 372 (52.4%) patients had 592 acquired chromosome gain(s) ( Figure 2B) ; +21 was the most frequent (n=106, 28.5%), followed by +19 (n=93, 25.0%), +8 (n=77, 20.7%), +6 (n=58, 15.6%), and +2 (n=39, 10.5%). A patient had TMD at 7 weeks old and developed AMKL at 7 months old. 16 In this patient, blast cells at both episodes showed +21, but GATA1 mutation was detected only at the (Table 2 ). Most common recurrent alterations were t(1;22)(p13;q13) (n=51) and 11q23 rearrangements (n=38). Of 51 patients with t(1;22), 38 had balanced translocations, 2 had unbalanced translocations, and 11 had both. The cytogenetic abnormalities involving the 11q23 region were t(9;11)(p22;q23) (n=21), t(10;11)(p12;q23) (n=6), t(4;11)(q21;q23) and t(11;19)(q23;p13) (n=2 each), and others (n=7). Among the other 7 partners of 11q23, 14q23 (CEP170B or GPHN) has been previously recognized and the remaining were Xq22, 7p15, 8q13, 9q22, 17q23, and unknown. MLL rearrangements were confirmed in 21 of 38 patients by FISH, RT-PCR, or Southern blotting: 15 with t(9;11) (2 had incomplete cytogenetic data), 4 with t(10;11), and 1 each with t(4;11) and t(11;19). Notably, 1 patient with t(11;14)(q23;q22) also had t(1;22).
Many recurrent abnormalities were identified mostly within complex karyotypes.
Of 25 patients with 3q abnormalities, 5 also had a -7, which is a known association. Of these 25 patients, 14 had 3q21 and/or 3q26 breakpoints and 1 had a t(3;21)(q24;q22).
Of 28 patients with 5q abnormalities, 7 had deletions and 17 had translocations.
Interestingly, 7p and 7q abnormalities were frequently detected (n=43 and n=31, respectively), and most abnormalities were in complex karyotypes. The 7p included translocation (n=21), addition (n=9), deletion (n=5), ring (n=5), inversion (n=4), and insertion (n=1) (supplemental Table 5 ). The 7q included translocation (n=12), deletion (n=6, 2 with 5q-), ring (n=5), addition (n=4), and isochromosome (n=2). Chromosome 8 had only 2 recurrent aberrations: t(8;21)(q22;q22) and t(8;16)(p11.2;p13.3). Of 23 patients with 9q abnormalities, 10 had deletions, 2 had t(9;22)(q34;q11.2), and 1 had t(6;9)(p21;q34). For non-11q23 chromosome 11 abnormalities, 3 patients had t(10;11)(p12;q14) and 8 had breakpoints in 11p15 (mapping of NUP98 gene). The 12p abnormality occurred in 16 patients: 6 had a deletion and 10 had mostly balanced rearrangements, including 2 with inv(12)(p13q13) and 1 with t(5;12)(p13;p13). Notably, 5 of the 16 12p abnormalities were associated with known recurrent abnormalities: t(4;11), t(8;16), t(6;9), t(8;21), and inv (16) and abnormalities of 17p [3] ) changes. No patient had -7 or t(9;22), and 2 patients with 7q-were considered to have structural changes because 7q-was not associated with poor outcome in a pediatric international retrospective study.
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Comprehensive cross-tabulation was done to evaluate overlaps among cytogenetic subgroups (supplemental Table 6 ). At P<0.0001, +6 ,+8, +10, +19, and +21
were significantly associated with each other, although +21 was not strongly associated with +10. Also, +1 was associated with t(1;22) due to high frequency of the unbalanced pattern, abnormality of 7p was associated with abnormalities of 7q and 8q, and t(9;11) was associated with +19. Complex karyotype was associated with +1, +6, abnormalities of 7p, +8, +10, +19, and +21, and numerical or structural changes among 49-65 chromosomes were associated with +1, +6, +8, +10, and +19.
Clinical features and outcomes by cytogenetic subtype
Patients with hypodiploidy were significantly older at diagnosis (median 2.97 years, P=0.003) than those with normal karyotype, pseudodiploidy, 47-50 chromosomes, and more than 50 chromosomes ( Table 2 ).
Extramedullary or CNS disease was not associated with a particular cytogenetic subgroup.
There were no significant differences in outcomes between patients for whom cytogenetic information was or was not available ( and 0.006) were associated with significantly worse outcomes, whereas 7p abnormalities were associated with better outcomes (P=0.004 and 0.004) ( Table 3 and Figure 3 ). Patients with -13 and 9p abnormalities other than t(9;11) had a poorer EFS (P=0.040) and OS (P=0.021), respectively, than those in other subgroups.
For (Figure 4A-B) .
Discussion
We report herein the largest international collaborative study of pediatric AMKL. AMKL was seen in 7.8% of pediatric patients with AML in this retrospective study. The most common recurrent cytogenetic abnormalities were t(1;22) and those involving 11q23, mostly t(9;11). Interestingly, prognosis was significantly worse in patients with t(9;11) and normal karyotype and better in those with 7p abnormalities. Consistent with survival data on patients with AML, 19 AMKL patients in our study diagnosed in or after 2000 had better prognosis than those diagnosed earlier. This is possibly related to administration of intensified chemotherapy, especially higher doses of cytarabine, and better supportive care in the recent era than in previous eras. findings from other studies. 1, 3, 28 The biology of acquired +21 is different from that of DSassociated AMKL, which is associated with significantly better outcomes; GATA1 mutations; and frequent mutations in the cohesin complex, EZH2 and other epigenetic regulators, and JAK family kinases.
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Because AMKL is frequently associated with myelofibrosis and seen in young children, it is often difficult to obtain sufficient material for cytogenetic analysis. We do not have cytogenetic data for 118 (24.1%) patients, and the results need to be interpreted with caution; however, the prognosis of patients for whom cytogenetic information was and was not available did not differ. Considering these characteristics and the retrospective nature of this study, we believe that the availability of cytogenetic anthracycline and cytarabine backbone, including HSCT for some patients, and we were able to evaluate the changes in chemotherapy intensity over time, which can be associated with improved survival of patients in the recent era. International collaborations are essential to study relatively rare leukemia subgroups such as AMKL.
In conclusion, our data highlight the great heterogeneity in cytogenetic findings of patients with AMKL and show that patients allocated to some specific cytogenetic subgroups have significantly different outcomes, which enables the classification of pediatric AMKL patients into 3 risk groups according to prognosis for risk-based therapy. 
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